Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine

Stevens, R. H.; LaVoy, Alora; Nordone, Shila K.; Burkhard, MaryJo; Dean, Gregg A.

doi:10.1016/j.vaccine.2004.09.033

Cited by 35 publications

(34 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with those seen by Stevens at al. [28] and suggest that pre-existing anti-Lm immunity does not preclude the use of this vector for vaccine delivery.…”

Section: Discussionmentioning

confidence: 99%

“…Second, foreign antigens encoded by Lm are efficiently presented by both MHC class I and MHC class II molecules after being processed to peptides [23,24]; as Lm vectors deliver antigens directly to the DC cytosol, both CD8 + and CD4 + antigen-specific T cells can thus be activated [22]. Third, because the natural route of Lm infection involves oral exposure, Listeria-derived vaccine vectors may be given orally [25][26][27][28]. Fourth, evidence with a Listeria vector containing two genes of feline immunodeficiency virus (FIV) showed that pre-existing immunity against Lm does not preclude the generation of immunity to foreign antigens expressed by the Listeria vector [28].…”

Section: Introductionmentioning

confidence: 99%

“…Third, because the natural route of Lm infection involves oral exposure, Listeria-derived vaccine vectors may be given orally [25][26][27][28]. Fourth, evidence with a Listeria vector containing two genes of feline immunodeficiency virus (FIV) showed that pre-existing immunity against Lm does not preclude the generation of immunity to foreign antigens expressed by the Listeria vector [28].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys

Jiang

Rasmussen

Nolan

et al. 2007

Vaccine

View full text Add to dashboard Cite

Induction of strong cellular immunity will be important for AIDS vaccine candidates. Natural infection with wild-type Listeria monocytogenes (Lm), an orally transmitted organism, is known to generate strong cellular immunity, thus raising the possibility that live attenuated Lm could serve as a vaccine vector. We sought to examine the potential of live attenuated Lm to induce cellular immune responses to HIV Gag. Rhesus macaques were immunized with Lmdd-gag that expresses HIV gag and lacks two genes in the D-alanine (D-ala) synthesis pathway. Without this key component of the bacterial cell wall, vaccine vector replication critically depends on exogenous D-ala. Lmdd-gag was given to animals either solely orally or by oral priming followed by intramuscular (i.m.) boosting; D-ala was co-administered with all vaccinations. Lmdd-gag and D-ala were well tolerated. Oral priming/oral boosting induced Gag-specific cellular immune responses, whereas oral priming/i.m. boosting induced systemic as well as mucosal anti-Gag antibodies. These results suggest that the route of vaccination may bias anti-Gag immune responses either towards T-helper type 1 (Th1) or Th2 responses; overall, our data show that live attenuated, recombinant Lmdd-gag was safe and immunogenic in primates.

show abstract

“…These results are consistent with those seen by Stevens at al. [28] and suggest that pre-existing anti-Lm immunity does not preclude the use of this vector for vaccine delivery.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys

Jiang

Rasmussen

Nolan

et al. 2007

Vaccine

View full text Add to dashboard Cite

show abstract

“…These advantages include practical considerations, such as straightforward fermentation methods for manufacturing, and other desirable features, such as the ability to repeat administer even in the presence of protective L. monocytogenes-specific immunity (6,40,41). One compelling rationale for this vaccine platform is based on the well-known correlates of protection in the mouse listeriosis model: longlived functional CD4…”

mentioning

confidence: 99%

Constitutive Activation of the PrfA Regulon Enhances the Potency of Vaccines Based on Live-Attenuated and Killed but Metabolically Active Listeria monocytogenes Strains

et al. 2008

View full text Add to dashboard Cite

Recognition of the advantages of recombinant Listeria monocytogenes-based vaccines compared to those of other recombinant-vaccine platforms has facilitated the ongoing development and current evaluation of the former in early-phase clinical trials. These advantages include practical considerations, such as straightforward fermentation methods for manufacturing, and other desirable features, such as the ability to repeat administer even in the presence of protective L. monocytogenes-specific immunity (6,40,41). One compelling rationale for this vaccine platform is based on the well-known correlates of protection in the mouse listeriosis model: longlived functional CD4 ϩ and CD8 ϩ memory T cells induced in response to a single immunization with L. monocytogenes (19,28). There are now numerous publications that demonstrate the striking efficacy of recombinant L. monocytogenes vaccines in several animal models due to robust innate and adaptive cellular immunity (9,10,29). Recombinant L. monocytogenesbased vaccines represent an emerging approach to addressing an acute global need for effective vaccines that elicit functional cellular immunity to prevent or treat infections such as human immunodeficiency virus infection, hepatitis C virus infection, tuberculosis, and malaria as well as cancer.As L. monocytogenes is a food-borne pathogen having increased virulence among immunocompromised individuals, attenuated vaccine platforms are a prerequisite for advancement to evaluation with humans (23). We have previously described both live-attenuated and photochemically inactivated vaccine platforms derived from the wild-type (WT) strain 10403S (8, 9). The live-attenuated vaccine strain is deleted of both the actA and the inlB virulence genes (L. monocytogenes ⌬actA ⌬inlB vaccine strain), which in combination limit growth in the liver, a principal target organ of infection by the WT organism. Liver toxicity in mice, as measured by serum liver function tests for alanine transaminase and aspartate transaminase, is dramatically lower in mice injected intravenously (i.v.) with the L. monocytogenes ⌬actA ⌬inlB strain than in those injected i.v. with WT L. monocytogenes. Furthermore, liver toxicity was minimal and not dose limiting in two toxicology studies performed under good laboratory practice guidelines with cynomolgus monkeys given escalating doses of L. monocytogenes ⌬actA ⌬inlB-based strains (unpublished data). The L. monocytogenes ⌬actA ⌬inlB vaccine strain forms the basis for two ongoing FDA-approved phase 1 clinical trials being conducted with adult subjects with advanced cancers. The second vaccine platform, termed "killed but metabolically active" (KBMA), is derived from the L. monocytogenes ⌬actA ⌬inlB vaccine strain and is deleted of both uvrA and uvrB, genes encoding the DNA

show abstract

“…Listeria monocytogenes, a gram-positive bacterium, has been used successfully in several studies performed with different animal models to deliver tumor, viral, or parasite antigens, as well as different cytokines either as secreted protein (13,23,34) or as plasmid-encoded DNA (21,32,35). A number of biological properties make L. monocytogenes a promising platform for the development of vaccines, particularly vaccines against infectious diseases or tumors.…”

mentioning

confidence: 99%

Comparison of Different Live Vaccine Strategies In Vivo for Delivery of Protein Antigen or Antigen-Encoding DNA and mRNA by Virulence-AttenuatedListeria monocytogenes

et al. 2006

View full text Add to dashboard Cite

Listeria monocytogenes can be used to deliver protein antigens or DNA and mRNA encoding such antigens directly into the cytosol of host cells because of its intracellular lifestyle. In this study, we compare the in vivo efficiencies of activation of antigen-specific CD8 and CD4 T cells when the antigen is secreted by L. monocytogenes or when antigen-encoding plasmid DNA or mRNA is released by self-destructing strains of L. monocytogenes. Infection of mice with self-destructing L. monocytogenes carriers delivering mRNA that encodes a nonsecreted form of ovalbumin (OVA) resulted in a significant OVA-specific CD8 T-cell response. In contrast, infection with L. monocytogenes delivering OVA-encoding DNA failed to generate specific T cells. Secretion of OVA by the carrier bacteria yielded the strongest immune response involving OVA-specific CD8 and CD4 T cells. In addition, we investigated the antigen delivery capacity of a self-destructing, virulence-attenuated L. monocytogenes aroA/B mutant. In contrast to the wild-type strain, this mutant exhibited only marginal liver toxicity when high doses (5 ؋ 10 7 CFU per animal administered intravenously) were used, and it was also able to deliver sufficient amounts of secreted OVA into mice. Therefore, the results presented here could lay the groundwork for a rational combination of L. monocytogenes as an attenuated carrier for the delivery of protein and nucleic acid vaccines in novel vaccination strategies.The use of virulence-attenuated bacteria as carriers for heterologous protein antigens is a versatile vaccination approach (for a review see reference 15). Bacteria directly target vaccine antigens to the appropriate cells of the immune system, such as dendritic cells (DC), for antigen presentation (17), and they act as strong immune potentiators due to their naturally produced bacterial components (pathogen-associated molecular patterns) that stimulate and modulate early innate immune responses, encouraging the generation of robust and long-lasting adaptive immune responses (11).In the majority of cases so far, virulence-attenuated strains of enteric bacterial pathogens like Salmonella, Shigella, Yersinia, Vibrio, Escherichia coli, or Listeria have been used for vaccine delivery (15). These bacteria, which can be inoculated orally, are able to cross the intestinal mucosa and induce systemic immunity as well as mucosal immunity. Therefore, virulence-attenuated bacteria are optimal candidates as carriers for heterologous protein antigens, antigen-encoding DNA (DNA vaccines), and other molecules for vaccination or other therapeutic purposes (15).In particular, the bacteria that are able to replicate and release antigen within the cytosol of eukaryotic host cells are attractive candidates for the elicitation of cell-mediated immunity against heterologous antigens. Listeria monocytogenes, a gram-positive bacterium, has been used successfully in several studies performed with different animal models to deliver tumor, viral, or parasite antigens, as well as different cytokines...

show abstract

Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine

Cited by 35 publications

References 56 publications

Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys

Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys

Constitutive Activation of the PrfA Regulon Enhances the Potency of Vaccines Based on Live-Attenuated and Killed but Metabolically Active Listeria monocytogenes Strains

Comparison of Different Live Vaccine Strategies In Vivo for Delivery of Protein Antigen or Antigen-Encoding DNA and mRNA by Virulence-AttenuatedListeria monocytogenes

Contact Info

Product

Resources

About